Biogen Inc. (NASDAQ: BIIB) reported first quarter 2021 earnings results today. Total revenues decreased 24% year-over-year to $2.6 billion. On a constant currency basis, revenues fell 25%. Net income attributable to Biogen amounted to $410 million, or $2.69 per share, compared to $1.4 billion, or $8.08 per share. Adjusted net income was $813 million, or […]
“Biogen Inc. (NASDAQ: BIIB) reported first quarter 2021 earnings results today. Total revenues decreased 24% year-over-year to $2.6 billion. On a constant currency basis, revenues fell 25%. Net income attributable to Biogen amounted to $410 million, or $2.69 per share, compared to $1.4 billion, or $8.08 per share. Adjusted net income was $813 million, or […]
· April 22, 2021
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2021 earnings results today.
Total revenues decreased 24% year-over-year to $2.6 billion. On a constant currency basis, revenues fell 25%.
Net income attributable to Biogen amounted to $410 million, or $2.69 per share, compared to $1.4 billion, or $8.08 per share. Adjusted net income was $813 million, or $5.34 per share.
For the full year of 2021, Biogen expects total revenue of $10.45-10.75 billion and adjusted EPS of $17.50-19.00.
